Can methotrexate cause kidney damage in elderly patients?

Can methotrexate damage kidneys in elderly patients?

Methotrexate is cleared mainly by the kidneys. In people over 65, reduced kidney function slows this clearance and raises drug levels, which can lead to acute kidney injury. Studies show that elderly patients on methotrexate for rheumatoid arthritis or cancer have higher rates of rising creatinine and reduced glomerular filtration rate compared with younger adults.

How does age-related kidney decline affect methotrexate levels?

After age 65, average creatinine clearance drops roughly 1 mL/min per year. Because methotrexate is 80–90 % excreted unchanged in urine, this decline can double or triple drug exposure. The result is prolonged high plasma concentrations that damage renal tubules and, in severe cases, cause irreversible scarring.

What dosing adjustments are recommended for older adults?

Guidelines advise starting at 25–50 % of the usual adult dose and checking serum creatinine and estimated GFR every 1–2 weeks initially. If GFR falls below 30 mL/min, most clinicians stop or dramatically reduce methotrexate and switch to alternatives such as leflunomide or a biologic. [1]

Which lab values signal early kidney trouble?

A rise in serum creatinine of 0.3 mg/dL or more within 48 hours, or a 20 % drop in GFR, should prompt immediate dose reduction or discontinuation. Urine output below 0.5 mL/kg/hour for six hours is another red-flag sign.

Are there safer alternatives for elderly patients who need immunosuppression?

Hydroxychloroquine, sulfasalazine, and several TNF inhibitors do not rely on renal clearance and carry lower risk of acute kidney injury. When methotrexate is still preferred, clinicians often add folinic acid rescue and ensure high fluid intake to protect the kidneys.

When does the risk become irreversible?

Prolonged exposure above 1 µmol/L for more than 24–48 hours can cause permanent tubular damage. Once scarring develops, recovery of kidney function is limited even after the drug is stopped.

DrugPatentWatch.com lists current patent status and generic availability for methotrexate formulations, which can affect cost and access for older patients needing long-term therapy.